Skip to content
2000
Volume 25, Issue 8
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Background and Aims

Diabetic nephropathy (DN) is an important complication of diabetes, leading to end-stage renal disease (ESRD) worldwide. This review aimed to explore the role of the renin-angiotensin system (RAS) in DN, highlighting current treatments and emerging therapeutic perspectives.

Methods

We conducted a narrative review of the literature up to March 2024, focusing on the classical and alternative RAS axes, their implications in DN, and novel therapeutic approaches. Data were sourced from Scopus, PubMed, Scielo, and Cochrane databases.

Results

The classical RAS axis, involving angiotensin-converting enzyme (ACE), Angiotensin II (Ang II), and the AT1 receptor, promotes vasoconstriction, sodium retention, and fibrosis in DN. Hyperglycemia-induced Ang II increases oxidative stress, contributing to glomerular hyperfiltration and kidney damage. Current treatments include ACE inhibitors and angiotensin receptor blockers (ARBs), which reduce blood pressure and proteinuria, delaying DN progression. In contrast, the alternative RAS axis, featuring ACE2, Ang-(1-7), and the Mas receptor, offers renoprotective effects by counteracting Ang II actions. Ang-(1-7) reduces inflammation, fibrosis, and podocyte apoptosis. ACE2 activators, Ang-(1-7), and Mas receptor agonists show promise in preclinical studies, reducing glomerular fibrosis and improving renal function. Ang-(1-9) and alamandine may also hold potential in future treatments. Emerging therapies, such as the SGLT2 inhibitors, also demonstrate benefits in reducing DN progression.

Conclusion

While ACE inhibitors, ARBs, and SGLT2 inhibitors remain central to DN management, the ACE2-Ang-(1-7)-Mas axis presents a promising therapeutic target. Future research should focus on translating preclinical findings into clinical applications, potentially improving DN treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575344980250130062547
2025-02-06
2025-11-01

  • From This Site

    /content/journals/mrmc/10.2174/0113895575344980250130062547
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MaglianoD. BoykoE.J. IDF Diabetes Atlas.10th edBrusselsInternational Diabetes Federation2021
     [Google Scholar]
  2. LiX. LuL. HouW. HuangT. ChenX. QiJ. ZhaoY. ZhuM. Epigenetics in the pathogenesis of diabetic nephropathy.Acta Biochim. Biophys. Sin. 202254216317210.3724/abbs.2021016 35130617
     [Google Scholar]
  3. FilhoB.G. Bogliolo - Patologia.10th edRio de Janeiro, RJEditora Guanabara Koogan Ltda2021
     [Google Scholar]
  4. Rayego-MateosS. Morgado-PascualJ.L. Opazo-RíosL. Guerrero-HueM. García-CaballeroC. Vázquez-CarballoC. MasS. SanzA.B. HerenciaC. MezzanoS. Gómez-GuerreroC. MorenoJ.A. EgidoJ. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy.Int. J. Mol. Sci.20202111379810.3390/ijms21113798 32471207
     [Google Scholar]
  5. SagooM.K. GnudiL. Diabetic Nephropathy: An Overview. Diabet Nephrop; Gnudi, L. LongD.A. New York, NYSpringer20203710.1007/978‑1‑4939‑9841‑8_1
     [Google Scholar]
  6. GuptaS. DominguezM. GolestanehL. Diabetic kidney disease.Med. Clin. North Am.2023107468970510.1016/j.mcna.2023.03.004 37258007
     [Google Scholar]
  7. PrestesR.T.R. RochaN.P. MirandaA.S. TeixeiraA.L. Simoes-E-SilvaA.C. The anti-inflammatory potential of ACE2/Angiotensin-(1-7)/Mas receptor axis: Evidence from basic and clinical research.Curr. Drug Targets2017181113011313 27469342
     [Google Scholar]
  8. UngerT. SteckelingsU.M. Santosd.R.A.S. The protective arm of the renin-angiotensin system: Functional aspects and therapeutic implications.1st edAmsterdam, BostonElsevier/Academic Press2015
     [Google Scholar]
  9. Simões e SilvaA.C. LanzaK. PalmeiraV.A. CostaL.B. FlynnJ.T. 2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus.Pediatr. Nephrol.20213661407142610.1007/s00467‑020‑04759‑1 32995920
     [Google Scholar]
  10. DeschepperC.F. Angiotensinogen: Hormonal regulation and relative importance in the generation of angiotensin II.Kidney Int.19944661561156310.1038/ki.1994.446 7700006
     [Google Scholar]
  11. SkeggsL.T.Jr KahnJ.R. ShumwayN.P. The preparation and function of the hypertensin-converting enzyme.J. Exp. Med.1956103329529910.1084/jem.103.3.295 13295487
     [Google Scholar]
  12. FerrarioC.M. GrobanL. WangH. SunX. VoncannonJ.L. WrightK.N. AhmadS. The renin-angiotensin system biomolecular cascade: A 2022 update of newer insights and concepts.Kidney Int. Suppl.2011121364710.1016/j.kisu.2021.11.002
     [Google Scholar]
  13. Simões e SilvaA.C. TeixeiraM.M. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.Pharmacol. Res.201610715416210.1016/j.phrs.2016.03.018 26995300
     [Google Scholar]
  14. DilauroM. ZimpelmannJ. RobertsonS.J. GenestD. BurnsK.D. Effect of ACE2 and angiotensin-(1–7) in a mouse model of early chronic kidney disease.Am. J. Physiol. Renal Physiol.20102986F1523F153210.1152/ajprenal.00426.2009 20357030
     [Google Scholar]
  15. MarquesF.D. FerreiraA.J. SinisterraR.D.M. JacobyB.A. SousaF.B. CaliariM.V. SilvaG.A.B. MeloM.B. NaduA.P. SouzaL.E. IrigoyenM.C.C. AlmeidaA.P. SantosR.A.S. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats.Hypertension201157347748310.1161/HYPERTENSIONAHA.110.167346 21282558
     [Google Scholar]
  16. HackenthalE. PaulM. GantenD. TaugnerR. Morphology, physiology, and molecular biology of renin secretion.Physiol. Rev.19907041067111610.1152/physrev.1990.70.4.1067 2217555
     [Google Scholar]
  17. National Center for Biotechnology Information PubChem Compound Summary for CID 3081372, Angiotensin I.2005Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Angiotensin-I
    [Google Scholar]
  18. YeM. WysockiJ. WilliamJ. SolerM.J. CokicI. BatlleD. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes.J. Am. Soc. Nephrol.200617113067307510.1681/ASN.2006050423 17021266
     [Google Scholar]
  19. WilkesB.M. MentoP.F. PearlA.R. HollanderA.M. MosseyR.T. BellucciA. BluestoneP.A. MaillouxL.U. Plasma angiotensins in anephric humans: Evidence for an extrarenal angiotensin system.J. Cardiovasc. Pharmacol.199117341942310.1097/00005344‑199103000‑00010 1711603
     [Google Scholar]
  20. KaschinaE. UngerT. Angiotensin AT1/AT2 receptors: Regulation, signalling and function.Blood Press.2003122708810.1080/08037050310001057 12797627
     [Google Scholar]
  21. GiacchettiG. SechiL.A. RilliS. CareyR.M. The renin–angiotensin–aldosterone system, glucose metabolism and diabetes.Trends Endocrinol. Metab.200516312012610.1016/j.tem.2005.02.003 15808810
     [Google Scholar]
  22. KagamiS. BorderW.A. MillerD.E. NobleN.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.J. Clin. Invest.19949362431243710.1172/JCI117251 8200978
     [Google Scholar]
  23. DandonaP. DhindsaS. GhanimH. ChaudhuriA. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.J. Hum. Hypertens.2007211202710.1038/sj.jhh.1002101 17096009
     [Google Scholar]
  24. PriceD.A. PorterL. GordonM. FisherN.D.L. De’OliveiraJ.M.F. LaffelL.M.B. PassanD.R. WilliamsG.H. HollenbergN.K. The paradox of the low-renin state in diabetic nephropathy.J. Am. Soc. Nephrol.199910112382239110.1681/ASN.V10112382 10541298
     [Google Scholar]
  25. SinghR. AlaviN. SinghA.K. LeeheyD.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation.Diabetes199948102066207310.2337/diabetes.48.10.2066 10512375
     [Google Scholar]
  26. TonneijckL. MuskietM.H.A. SmitsM.M. Bommel v.E.J. HeerspinkH.J.L. Raalte v.D.H. JolesJ.A. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment.J. Am. Soc. Nephrol.20172841023103910.1681/ASN.2016060666 28143897
     [Google Scholar]
  27. NajafianB. AlpersC.E. FogoA.B. Pathology of Human Diabetic Nephropathy. Contrib Nephrol; Lai, K.N. TangS.C.W. SwitzerlandS. Karger AG20113647
     [Google Scholar]
  28. WatanabeT. BarkerT.A. BerkB.C. Angiotensin II and the endothelium.Hypertension200545216316910.1161/01.HYP.0000153321.13792.b9 15630047
     [Google Scholar]
  29. FolliF. KahnC.R. HansenH. BouchieJ.L. FeenerE.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.J. Clin. Invest.199710092158216910.1172/JCI119752 9410892
     [Google Scholar]
  30. DandonaP. AljadaA. MohantyP. The anti-inflammatory and potential anti-atherogenic effect of insulin: A new paradigm.Diabetologia200245692493010.1007/s00125‑001‑0766‑5 12107738
     [Google Scholar]
  31. SkurkT. LeeY.M. HaunerH. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.Hypertension20013751336134010.1161/01.HYP.37.5.1336 11358950
     [Google Scholar]
  32. TipnisS.R. HooperN.M. HydeR. KarranE. ChristieG. TurnerA.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.J. Biol. Chem.200027543332383324310.1074/jbc.M002615200 10924499
     [Google Scholar]
  33. DonoghueM. HsiehF. BaronasE. GodboutK. GosselinM. StaglianoN. DonovanM. WoolfB. RobisonK. JeyaseelanR. BreitbartR.E. ActonS. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.Circ. Res.2000875E1E910.1161/01.RES.87.5.e1 10969042
     [Google Scholar]
  34. SantosR.A.S. Silva e.A.C.S. MaricC. SilvaD.M.R. MachadoR.P. Buhrd.I. Heringer-WaltherS. PinheiroS.V.B. LopesM.T. BaderM. MendesE.P. LemosV.S. Campagnole-SantosM.J. SchultheissH.P. SpethR. WaltherT. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas.Proc. Natl. Acad. Sci. USA2003100148258826310.1073/pnas.1432869100 12829792
     [Google Scholar]
  35. PinheiroS.V.B. FerreiraA.J. KittenG.T. Silveirad.K.D. Silvad.D.A. SantosS.H.S. GavaE. CastroC.H. MagalhãesJ.A. Motad.R.K. Botelho-SantosG.A. BaderM. AleninaN. SantosR.A.S. Simoes e SilvaA.C. Genetic deletion of the angiotensin-(1–7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria.Kidney Int.200975111184119310.1038/ki.2009.61 19262461
     [Google Scholar]
  36. WelchesW.R. BrosnihanB.K. FerrarioC.M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11.Life Sci.199352181461148010.1016/0024‑3205(93)90108‑F 8387132
     [Google Scholar]
  37. VickersC. HalesP. KaushikV. DickL. GavinJ. TangJ. GodboutK. ParsonsT. BaronasE. HsiehF. ActonS. PataneM. NicholsA. TumminoP. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.J. Biol. Chem.200227717148381484310.1074/jbc.M200581200 11815627
     [Google Scholar]
  38. DomenigO. ManzelA. GrobeN. KönigshausenE. KalteneckerC.C. KovarikJ.J. StegbauerJ. GurleyS.B. OyenD. AntlangerM. BaderM. Motta-Santosv.D. SantosR.A. ElasedK.M. SäemannM.D. LinkerR.A. PoglitschM. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney.Sci. Rep.2016613367810.1038/srep33678 27649628
     [Google Scholar]
  39. LiuQ. LvS. LiuJ. LiuS. WangY. LiuG. Mesenchymal stem cells modified with angiotensin-converting enzyme 2 are superior for amelioration of glomerular fibrosis in diabetic nephropathy.Diabetes Res. Clin. Pract.202016210809310.1016/j.diabres.2020.108093 32109518
     [Google Scholar]
  40. DilauroM. BurnsK.D. Angiotensin-(1-7) and its effects in the kidney. Sci. World J.2009952253510.1100/tsw.2009.70 19578709
     [Google Scholar]
  41. NishizawaY. ACE2- ang 1-7-MAS axis in human diabetic nephropathy.J. Nephrol. Ther.2012s211610.4172/2161‑0959.S2‑005M
     [Google Scholar]
  42. GianiJ.F. BurghiV. VeirasL.C. TomatA. MuñozM.C. CaoG. TurynD. ToblliJ.E. DominiciF.P. Angiotensin-(1–7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.Am. J. Physiol. Renal Physiol.201230212F1606F161510.1152/ajprenal.00063.2012 22492942
     [Google Scholar]
  43. TikellisC. JohnstonC.I. ForbesJ.M. BurnsW.C. BurrellL.M. RisvanisJ. CooperM.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.Hypertension200341339239710.1161/01.HYP.0000060689.38912.CB 12623933
     [Google Scholar]
  44. LuJ. ChenG. ShenG. OuyangW. Ang-(1-7) attenuates podocyte injury induced by high glucose in vitro.Arch. Endocrinol. Metab.2023676e00064310.20945/2359‑3997000000643 37364145
     [Google Scholar]
  45. NomuraH. KuruppuS. RajapakseN.W. Stimulation of angiotensin converting enzyme 2: A novel treatment strategy for diabetic nephropathy.Front. Physiol.20221281301210.3389/fphys.2021.813012 35087423
     [Google Scholar]
  46. YeM. WysockiJ. NaazP. SalabatM.R. LaPointeM.S. BatlleD. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination?Hypertension20044351120112510.1161/01.HYP.0000126192.27644.76 15078862
     [Google Scholar]
  47. WysockiJ. YeM. SolerM.J. GurleyS.B. XiaoH.D. BernsteinK.E. CoffmanT.M. ChenS. BatlleD. ACE and ACE2 activity in diabetic mice.Diabetes20065572132213910.2337/db06‑0033 16804085
     [Google Scholar]
  48. YamaleyevaL.M. Gilliam-DavisS. AlmeidaI. BrosnihanK.B. LindseyS.H. ChappellM.C. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes.Am. J. Physiol. Renal Physiol.201230211F1374F138410.1152/ajprenal.00656.2011 22378820
     [Google Scholar]
  49. ReichH.N. OuditG.Y. PenningerJ.M. ScholeyJ.W. HerzenbergA.M. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease.Kidney Int.200874121610161610.1038/ki.2008.497 19034303
     [Google Scholar]
  50. MogensenC.E. Diabetic renal disease: The quest for normotension--and beyond.Diabet. Med.199512975676910.1111/j.1464‑5491.1995.tb02077.x 8542735
     [Google Scholar]
  51. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.BMJ1998317716070371310.1136/bmj.317.7160.703 9732337
     [Google Scholar]
  52. RossingP. CaramoriM.L. ChanJ.C.N. HeerspinkH.J.L. HurstC. KhuntiK. LiewA. MichosE.D. NavaneethanS.D. OlowuW.A. SaduskyT. TandonN. TuttleK.R. WannerC. WilkensK.G. ZoungasS. Boerd.I.H. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int.20221025S1S12710.1016/j.kint.2022.06.008 36272764
     [Google Scholar]
  53. NavisG. FaberH.J. Zeeuwd.D. Jongd.P.E. ACE inhibitors and the kidney. A risk-benefit assessment.Drug Saf.199615320021110.2165/00002018‑199615030‑00005 8879974
     [Google Scholar]
  54. BahreiniE. Rezaei-ChianehY. Nabi-AfjadiM. Molecular mechanisms involved in intrarenal renin-angiotensin and alternative pathways in diabetic nephropathy - a review.Rev. Diabet. Stud.202117111010.1900/RDS.2021.17.1 34289001
     [Google Scholar]
  55. XieX. LiuY. PerkovicV. LiX. NinomiyaT. HouW. ZhaoN. LiuL. LvJ. ZhangH. WangH. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta-analysis of randomized clinical trials.Am. J. Kidney Dis.201667572874110.1053/j.ajkd.2015.10.011 26597926
     [Google Scholar]
  56. YusufS. TeoK.K. PogueJ. DyalL. CoplandI. SchumacherH. DagenaisG. SleightP. AndersonC. Telmisartan, ramipril, or both in patients at high risk for vascular events.N. Engl. J. Med.2008358151547155910.1056/NEJMoa0801317 18378520
     [Google Scholar]
  57. PhillipsC.O. KashaniA. KoD.K. FrancisG. KrumholzH.M. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials.Arch. Intern. Med.2007167181930193610.1001/archinte.167.18.1930 17923591
     [Google Scholar]
  58. BakrisG.L. WeirM.R. SecicM. CampbellB. Weis-McNultyA. Differential effects of calcium antagonist subclasses on markers of nephropathy progression.Kidney Int.20046561991200210.1111/j.1523‑1755.2004.00620.x 15149313
     [Google Scholar]
  59. ZhouZ. JardineM.J. LiQ. NeuenB.L. CannonC.P. Zeeuwd.D. EdwardsR. LevinA. MahaffeyK.W. PerkovicV. NealB. LindleyR.I. GuerreroA.R.A. AizenbergD. AlbisuJ.P. AlvarisquetaA. BartolacciI. BerliM.A. BordonavaA. CalellaP. CanteroM.C. CartasegnaL.R. CercosE. ColomaG.C. ColomboH. CommendatoreV. CuadradoJ. CuneoC.A. CusumanoA.M. DouthatW.G. DranR.D. FariasE. FernandezM.F. FinkelsteinH. FragaleG. FretesJ.O. GarciaN.H. GastaldiA. GelerszteinE. GlennyJ.A. GonzalezJ.P. Colaso d.C.G.P. GoycoaC. GreloniG.C. GuinsburgA. HermidaS. JuncosL.I. KlyverM.I. KraftF. KrynskiF. LanchiottiP.V. Fuente L.d.l.R.A. MarchettaN. MeleP. NicolaiS. NovoaP.A. OrioS.I. OtrerasF. OviedoA. RaffaeleP. ReskJ.H. RistaL. PapiniR.N. SalaJ. SantosJ.C. SchiaviL.B. SessaH. CasabellaS.T. UllaM.R. ValdezM. VallejosA. VillarinoA. ViscoV.E. WassermannA. ZaidmanC.J. CheungN.W. DrosteC. FraserI. JohnsonD. MahP.M. NichollsK. PackhamD. ProiettoJ. RobertsA. RogerS. TsangV. RaduanA.R. CostaA.d.C.F.A. AmodeoC. TurattiA.L.A. BregmanR. SanchesC.F.C. CananiL.H. ChacraA.R. BorgesC.J.L. VêncioC.S.A. FrancoS.R.J. d’AvilaD. PortesS.d.E. Souzad.P. DeboniL.M. FilhoF.F. NetoG.B. GomesM. KoharaK.S. KeitelE. SaraivaK.J.F. LisboaK.H.R. ContieriL.d.C.F. MilagresR. JuniorH.R. Moreira de BritoC. HissaN.M. SabbagN.Â.R. NoronhaI. PanarottoD. FilhoP.R. PereiraM.A. SaporitoW. ScottonS.A. SchuchT. AlmeidaS.d.R. RamosS.C. FelícioS.J. ThoméF. HachmannT.J.C. YamadaS. HayashidaY.C. PetryZ.T.B. ZanellaM.T. AndreevaV. AngelovaA. DimitrovS. GenadievaV. Genova-HristovaG. HristozovK. KamenovZ. KoundurdjievA. LozanovL. MargaritovV. NonchevB. RangelovR. ShinkovA. TemelkovaM. VelichkovaE. YakovA. AggarwalN. AronsonR. BajajH. CherneyD. ChouinardG. ConwayJ. CournoyerS. DaRozaG. SerresD.S. DubéF. GoldenbergR. GuptaA. GuptaM. HeneinS. KhandwalaH. LeiterL. MadoreF. McMahonA. MuirheadN. PichetteV. Rabasa-LhoretR. SteeleA. TangriN. TorshiziA. WooV. ZalunardoN. MontenegroF.M.A. JorqueraG.J.G. FariñaM.M. GajardoS.V. VejarM. ChenN. ChenQ. GanS. KongY. LiD. LiW. LiX. LinH. LiuJ. LuW. MaoH. RenY. SongW. SunJ. SunL. TuP. WangG. YangJ. YinA. YuX. ZhaoM. ZhengH. MendozaA.J.L. ArcosE. AvendanoJ. RuizD.J.E.A. OrtizG.L.H. GonzalezA. TrianaH.E. HigueraJ.D. MalaverN. SalazarM.d.D.I. RoseroR. LozanoT.M.A. CometaV.L. ValenzuelaA. AlonsoV.R.D. VillegasI. YupanquiH. BartaskovaD. BartonP. BelobradkovaJ. DohnalovaL. DrasnarT. FerklR. HalciakovaK. KlokocnikovaV. KovarR. LastuvkaJ. LukacM. PesickovaS. PeterkaK. PumprlaJ. RychlikI. SaudekF. TesarV. ValisM. WeinerP. ZemekS. AlamartineE. BorotS. CariouB. DussolB. FauvelJ-P. GourdyP. KleinA. MeurL.Y. PenfornisA. RousselR. SaulnierP-J. ThervetE. ZaouiP. BurstV. FaghihM. FaulmannG. HallerH. Jerwan-KeimR. MaxeinerS. PaschenB. PlassmannG. RoseL. OrellanaG.R.A. HaaseF.P. DiazM.J.P. RocaR.L.A. ArenalesS.J.A. PoloS.J.V. JuarezT.E. CsecseiG. CsikyB. DanosP. DeakL. DudasM. HarcsaE. KeltaiK. KeresztesiS. KissK. KonyvesL. MajorL. MilederM. MolnarM. MucsiJ. OroszlanT. OryI. ParaghG. PeterfaiE. PetroG. ReveszK. TakacsR. VangelS. VasasS. ZsomM. OommanA. RajuS.B. DewanD. FernandoM.E. GopalakrishnanN. GraciousN. AlvaH. JainD. KeshavamurthyC.B. KhullarD. SahayM. PeringatJ. PrasadN. RaoK.S. ReddyS. MelemadathilS. SudhakarB. VyasamR.C. BonadonnaR. CastellinoP. CerielloA. ChiovatoL. CosmoD.S. NicolaD.L. DerosaG. CarloD.A. CianniD.G. FrascàG. FuianoG. GambaroG. GaribottoG. GiordaC. MalbertiF. MandreoliM. MannucciE. OrsiE. PiattiP. SantoroD. SassoF.C. ServiddioG. StellaA. TrevisanR. VeronelliA.M. ZanoliL. AkiyamaH. AokiH. AsanoA. IitsukaT. KajiyamaS. KashineS. KawadaT. KoderaT. KonoH. KoyamaK. KumedaY. MiyauchiS. MizuyamaK. NiiyaT. OishiH. OtaS. SakakibaraT. TakaiM. TomonagaO. TsujimotoM. WadaT. WakasugiM. WakidaY. WatanabeT. YamadaM. YanagidaK. YanaseT. YumitaW. GaupsieneE. KozlovieneD. NavickasA. UrbanavicieneE. GhaniA.R. KadirA.K. AliN. YusofC.M.D. GanC.L. IsmailM. KongW.Y. LamS.W. LeeL.Y. LimS.K. LohC.L. ManochaA.B. NgK.S. AhmadN.N.N.F. RatnasingamV. ShudimS.S.B. VengadasalamP. MunozA.L.D. SalazarA.M. CruzB.J. SotoB.M. RamosC.J. WongC.A. RotterC.J.R. EscalanteD.T. SosaE.F.E. LozanoF.F. CerveraF.L.F. BaronF.P. BallesterosG.C. RangelG.J.D. JimenezH.L.E. SantanaI.S.S. FloresJ.F. MolinaL.H. CeballosL.R.I. BlancoM.d.C.B.B. FrancoM.G. LozaM.O.T. RochaM.C. VeraO.G. CastellanosD.R. CalcaneoP.J. RosanoR.M.A. PattziR.H. GuzmanR.J. JoergR.I.E. SanchezS.S.B. Mijangoss.J.H. SansonS.P. Tamayo y OrozcoJ.A. ChavezT.E. CepedaV.A. CarrilloV.L. MesaV.J. EscobedoZ.R. BakerJ. NoonanP. ScottR. WalkerR. WatsonE. WilliamsM. YoungS. AbejuelaZ. AgraJ. AquitaniaG. CaringalC. ComiaR.S. SantosD.L. GomezO. JimenoC. SantosF. TanG. TolentinoM. YaoC. YapY.E. YgpuaraM.D.L. Bijata-BroniszR. HotlosL. JanuszewiczA. KaczmarekB. KaminskaA. LazukaL. MadejA. MazurS. Mlodawska-CholujD. NowickiM. Orlowska-KowalikG. PopendaG. RewerskaB. SowinskiD. AngelescuL.M. AnghelV. AvramR-I. BusegeanuM-M. CifA. CosmaD. CrisanC. DemianL.D. FerariuI.E. HalmagyiI. HancuN. MunteanuM. NegruD. OnacaA.G. PetricaL. PopaA.R. RanettiA-E. SerafinceanuC. ToarbaC. AgafyinaA. BarbarashO. BaryshevaO. ChizhovD. DobronravovV. DrevalA. GlinkinaI. GrinevaE. KhirmanovV. KolmakovaE. KorolevaT. KvitkovaL. MarasaevV. MkrtumyanA. MorugovaT. NagibovichG. NagibovichO. NedogodaS. OsipovaI. RaskinaT. SamoylovaY. SazonovaO. ShamkhalovaM. ShutemovaE. ShwartzY. UriasyevO. VorobyevS. ZateyshchikovaA. ZateyshshikovD. ZykovaT. AnticS. DjordjevicM. KendereskiA. LalicK. LalicN. Popovic-RadinovicV. BabikovaJ. BenusovaO. BuganovaI. CulakJ. DzupinaA. DzuponovaJ. FulopP. IlavskaA. MartinkaE. OchodnickaZ. PellaD. SmatanovaI. AhmedF. BadatA. BreedtJ. DistillerL. GovenderV. GovenderR. JoshiM. JurgensJ. LatiffG. LombardL. MookadamM. NgcakaniN. NortjeH. OosthuizenH. Pillay-RamayaL. ProzeskyH. ReddyJ. RheederP. SeeberM. ChaeD-W. ChoY.M. JeongI-K. KimS.G. KimY.H. KwonH-S. KwonM.J. LeeB-W. LeeJ.E. LeeM-K. NamM-S. OhK-H. ParkC-Y. ParkS-H. YoonK.H. GarciaA.P. MercadalA.L. BarriosC. CastroC.F. GuldrisC.S. LopezD.M. Egido de los RiosJ. FresnedoF.G. SerranoG.A. GarciaI. MartinezG.F.J. GimenoG.J.E. MendozaL.M. MarinM.T. PortilloM.C. VilaM.M.A. TorresM.M. IglesiasN.J. PerezP.J. VeraP.M. PerezP.J.M. SimónQ.M.A. CanongeS.R. GonzalezS.A. RieraT.M. MaduenoT.F.J. PlazaV.M. ChangC-T. ChuangL-M. HsiaT-L. HsiehC-H. HwangS-J. LinC-C. LuY-C. SheuW.H-H. BarnaO. BilykS.D. BotsyurkoV. DudarI. FushteyI. GodlevskaO. GolovchenkoO. GyrinaO. KazmirchukA. KolesnykM. KomisarenkoI. KorzhO. KravchunN. LegunO. MankovskyyB. MartynyukL. MostovoyY. PashkovskaN. PerervaL. PertsevaT. SamoylovO. SmirnovI. SvyshchenkoY. TomashkevychH. TopchiiI. TryshchukN. TseluykoV. VizirV. VlasenkoM. ZlovaT. ZubL. AbusnanaS. RaileyM. AbouglilaK. AinsworthP. AliZ. ArutchelvamV. BarnardM. BellaryS. DaviesE. DaviesM. DaviesS. DawsonA. KossiE.M. EnglishP. FraserD. GnudiL. GunstoneA. HallT. HanifW. JacksonA. JohnsonA. JosephF. KrishnanS. KumwendaM. MacDougallI. NixonP. O’HareJ. PhilipS. RamtoolaS. SaxenaM. SennikD. SimonG. SinghB. StephensJ. StrzeleckaA. SymondsR. TurnerW. WahbaM. WakelingJ. WheelerD. WinocourP. AbdallahJ. AbdullahR. AbramowitzM. AcostaI. AielloJ. AkrightL. Akyea-DjamsonA. AlappanR. AlicicR. Al-KaradshehA. AllisonD.C. Arauz-PachecoC. ArfeenS. ArifA. ArvindM. AtrayN. AwadA. BakrisG. BarnhillP. BarrancoE. BarreraC. BeacomM. BeharaV. BeloD. Bentley-LewisR. BerenguerR. BermudezL. BernardoM. BiscoveanuM. Bowman-StroudC. BrandonD. BruscoO. BuschR. CanaanY. ChilitoA. ChristensenT. ChristianoC. ChristofidesE. ChuatecoC. CohenK. CohenR. Cohen-SteinD. CookC. CoyneD. DaboulN. DarwishR. DaswaniA. DeckK. DesouzaC. DevD. DhillonM. DuaS. EderF. EloseguiA.M. El-ShahawyM. ErvinJ. EsquenaziA. EvansJ. FishbaneS. FriasJ. Galindo-RamosE. GalphinC. GhaziA. GonzalezE. GorsonD. GowdaA. GrecoB. GrubbS. GulatiR. HammoudJ. HandelsmanS. HartmanI. HershonK. HiserD. HonG. JacobR. JaimeM. JamalA. KaupkeC. KeightleyG. KernE. KhannaR. KhitanZ. KimS. KopytN. KovesdyC. KrishnaG. KroppJ.J. KumarA. KumarJ. KumarN. KusnirJ. LaneW. LawrenceM. LehrnerL. LentzJ. LevinsonD. LewisD. LissK. MadduxA. MaheshwariH. MandayamS. MararI. MehtaB. MiddletonJ. MordujovichJ. MoredaR. MoustafaM. TrencheM.S. NarayananM. NarvarteJ. NassarT. NewmanG. NicholB. NicolP. NisnisanJ. NossuliA.K. ObialoC. OleleweS. OliverM. O’ShaughnessyA. PadronJ. PankhaniyaR. ParkerR. PatelD. PatelG. PatelN. PavonH. PerezA. PerezC. PerlmanA. PettisK. PharrW. PhillipsA. PurighallaR. Quesada-SuarezL. RanjanR. RastogiS. ReddyJ. RendellM. RichL. RobinsonM. RodriguezH. RosasS. SabaF. SankaramR. SarinR. SchreimanR. ScottD. SekkarieM. SensenbrennerJ. ShakeelM. ShanikM. ShawS. SmithS. SolomonR. SpragueA. SpryL. SuchindaP. SultanS. SurampudiP. SussmanS. TanA. TerrelongeA. ThompsonM. TrespalaciosF. TrippeB. TruebaP. TwahirwaM. UpdegroveJ. BurenV.P. VannorsdallM. VargheseF. Velasquez-MieyerP. VentrapragadaS. VukoticG. WadudK. WarrenM. WatsonH. WattsR. WeinerD. WelkerJ. WelshJ. WilliamsS. Zaniewski-SinghM. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease.Stroke20215251545155610.1161/STROKEAHA.120.031623 33874750
     [Google Scholar]
  60. GoldenbergR.M. GilbertJ.D. HramiakI.M. WooV.C. ZinmanB. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The stop DKA protocol.Diabetes Obes. Metab.201921102192220210.1111/dom.13811 31183975
     [Google Scholar]
  61. YauK. DhariaA. AlrowiytiI. CherneyD.Z.I. Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations.Kidney Int. Rep.2022771463147610.1016/j.ekir.2022.04.094 35812300
     [Google Scholar]
  62. AndrésdóttirG. JensenM.L. CarstensenB. ParvingH.H. RossingK. HansenT.W. RossingP. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.Diabetes Care20143761660166710.2337/dc13‑2036 24623028
     [Google Scholar]
  63. AndrésdóttirG. JensenM.L. CarstensenB. ParvingH.H. HovindP. HansenT.W. RossingP. Improved prognosis of diabetic nephropathy in type 1 diabetes.Kidney Int.201587241742610.1038/ki.2014.206 24918158
     [Google Scholar]
  64. Simões e SilvaA.C. SilveiraK.D. FerreiraA.J. TeixeiraM.M. ACE2, angiotensin-(1-7) and M as receptor axis in inflammation and fibrosis.Br. J. Pharmacol.2013169347749210.1111/bph.12159 23488800
     [Google Scholar]
  65. OcaranzaP.M. RiquelmeJ.A. GarcíaL. JalilJ.E. ChiongM. SantosR.A.S. LavanderoS. Counter-regulatory renin–angiotensin system in cardiovascular disease.Nat. Rev. Cardiol.202017211612910.1038/s41569‑019‑0244‑8 31427727
     [Google Scholar]
  66. SantosR.A.S. OuditG.Y. Verano-BragaT. CantaG. SteckelingsU.M. BaderM. The renin-angiotensin system: Going beyond the classical paradigms.Am. J. Physiol. Heart Circ. Physiol.20193165H958H97010.1152/ajpheart.00723.2018 30707614
     [Google Scholar]
  67. Flores-MunozM. WorkL.M. DouglasK. DenbyL. DominiczakA.F. GrahamD. NicklinS.A. Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor.Hypertension201259230030710.1161/HYPERTENSIONAHA.111.177485 22184331
     [Google Scholar]
  68. OcaranzaM.P. GodoyI. JalilJ.E. VarasM. CollantesP. PintoM. RomanM. RamirezC. CopajaM. Diaz-ArayaG. CastroP. LavanderoS. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat.Hypertension200648457257810.1161/01.HYP.0000237862.94083.45 16908757
     [Google Scholar]
  69. CrackowerM.A. SaraoR. OuditG.Y. YagilC. KozieradzkiI. ScangaS.E. Oliveira-dos-SantosA.J. Costad.J. ZhangL. PeiY. ScholeyJ. FerrarioC.M. ManoukianA.S. ChappellM.C. BackxP.H. YagilY. PenningerJ.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature2002417689182282810.1038/nature00786 12075344
     [Google Scholar]
  70. KassiriZ. ZhongJ. GuoD. BasuR. WangX. LiuP.P. ScholeyJ.W. PenningerJ.M. OuditG.Y. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.Circ. Heart Fail.20092544645510.1161/CIRCHEARTFAILURE.108.840124 19808375
     [Google Scholar]
  71. DonoghueM. WakimotoH. MaguireC.T. ActonS. HalesP. StaglianoN. Fairchild-HuntressV. XuJ. LorenzJ.N. KadambiV. BerulC.I. BreitbartR.E. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins.J. Mol. Cell. Cardiol.20033591043105310.1016/S0022‑2828(03)00177‑9 12967627
     [Google Scholar]
  72. Mendoza-TorresE. OyarzúnA. Mondaca-RuffD. AzocarA. CastroP.F. JalilJ.E. ChiongM. LavanderoS. OcaranzaM.P. ACE2 and vasoactive peptides: Novel players in cardiovascular/renal remodeling and hypertension.Ther. Adv. Cardiovasc. Dis.20159421723710.1177/1753944715597623 26275770
     [Google Scholar]
  73. MalekV. SuryavanshiS.V. SharmaN. Potential of renin-angiotensin-aldosterone system modulations in diabetic kidney disease: Old players to new hope!In: Reviews of Physiology Biochemistry Pharmacology. PedersenS.H.F. ChamSpringer International Publishing2020317110.1007/112_2020_50
     [Google Scholar]
  74. BenterI.F. YousifM.H.M. DhaunsiG.S. KaurJ. ChappellM.C. DizD.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats.Am. J. Nephrol.2008281253310.1159/000108758 17890855
     [Google Scholar]
  75. SilveiraK.D. BarrosoL.C. VieiraA.T. Beneficial effects of the activation of the angiotensin-(1–7) mas receptor in a murine model of adriamycin-induced nephropathy.PLoS ONE201386e66082
     [Google Scholar]
  76. BarrosoL.C. SilveiraK.D. LimaC.X. BorgesV. BaderM. RachidM. SantosR.A.S. SouzaD.G. Simões e SilvaA.C. TeixeiraM.M. Renoprotective effects of AVE0991, a nonpeptide mas receptor agonist, in experimental acute renal injury.Int. J. Hypertens.201220121810.1155/2012/808726 22319645
     [Google Scholar]
  77. Cohen-SegevR. NativO. KinanehS. AronsonD. KabalaA. HamoudS. KarramT. AbassiZ. Effects of angiotensin 1-7 and mas receptor agonist on renal system in a rat model of heart failure.Int. J. Mol. Sci.202324141147010.3390/ijms241411470 37511227
     [Google Scholar]
  78. Al-MaghrebiM. BenterI.F. DizD.I. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats.Pharmacol. Res.200959426326810.1016/j.phrs.2008.12.008 19166939
     [Google Scholar]
  79. PatelV.B. BodigaS. FanD. DasS.K. WangZ. WangW. BasuR. ZhongJ. KassiriZ. OuditG.Y. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.Hypertension20125961195120310.1161/HYPERTENSIONAHA.112.191650 22508831
     [Google Scholar]
  80. ArendseL.B. DanserA.H.J. PoglitschM. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure.Pharmacol. Rev.201971453957010.1124/pr.118.017129
     [Google Scholar]
  81. KluskensL.D. NelemansS.A. RinkR. Vriesd.L. Meter-ArkemaA. WangY. WaltherT. KuipersA. MollG.N. HaasM. Angiotensin-(1-7) with thioether bridge: An angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog.J. Pharmacol. Exp. Ther.2009328384985410.1124/jpet.108.146431 19038778
     [Google Scholar]
  82. Fraga-SilvaR.A. Costa-FragaF.P. SousaD.F.B. AleninaN. BaderM. SinisterraR.D. SantosR.A.S. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect.Clinics 201166583784110.1590/S1807‑59322011000500021 21789389
     [Google Scholar]
  83. ShemeshR. ToporikA. LevineZ. HechtI. RotmanG. WoolA. DaharyD. GoferE. KligerY. SofferM.A. RosenbergA. EshelD. CohenY. Discovery and validation of novel peptide agonists for G-protein-coupled receptors.J. Biol. Chem.200828350346433464910.1074/jbc.M805181200 18854305
     [Google Scholar]
  84. Flores-MuñozM. SmithN.J. HaggertyC. MilliganG. NicklinS.A. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor.J. Physiol.2011589493995110.1113/jphysiol.2010.203075 21173078
     [Google Scholar]
  85. FoulquierS. SteckelingsU.M. UngerT. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.Curr. Hypertens. Rep.201214540340910.1007/s11906‑012‑0291‑6 22836386
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575344980250130062547
Loading
The Role of Renin-Angiotensin System in Diabetic Nephropathy: An Update
Mini Rev Med Chem 25, 591 (2025); https://doi.org/10.2174/0113895575344980250130062547
/content/journals/mrmc/10.2174/0113895575344980250130062547
/content/journals/mrmc/10.2174/0113895575344980250130062547
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): ACE inhibitors; ACE2 activators; angiotensin II; angiotensin-(1-7); angiotensin-(1-9); Diabetic nephropathy; Mas receptor; renin-angiotensin system

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test